Paolo Tarantino: ADCs – Gamechangers Beyond Oncology
Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X about a recent article by Ania M Jastreboff et al, published in The New England Journal of Medicine:
“ADCs: game-changers beyond oncology. In this randomized trial, MariTide (GLP1 agonist linked to an anti-GIP mAb) produced substantial weight loss in obese patients.
As per chemo-based ADCs, the mAb enables prolonged payload delivery, allowing Q4W administration.”
Title: Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Authors: Ania M Jastreboff, Donna H Ryan, Harold E Bays, Peter R Ebeling, Mia G Mackowski, Nisha Philipose, Leorah Ross, Yimeng Liu, Cassandra E Burns, Siddique A Abbasi, Nicola Pannacciulli
Read the Full Article on The New England Journal of Medicine
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023